You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 10, 2024

Claims for Patent: 6,296,873

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,296,873

Title:	Zero-order sustained release delivery system for carbamazephine derivatives
Abstract:	A zero-order sustained-release delivery system for delivery of carbamazepine or a derivative thereof. A polymeric matrix formulation of carbamazepine comprises hydrophilic polymer or hydrophilic/hydropholic polymer mixture which permits carbamazepine or carbamezepine derivative to be released from the polymer matrix in zero-order release kinetics.
Inventor(s):	Katzhendler; Ifat (Jerusalem, IL), Friedman; Michael (Jerusalem, IL)
Assignee:	Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL)
Application Number:	09/539,504
Patent Claims:	1. An erodible oral composition for sustained release delivery of carbamazepine or a derivative thereof at a zero-order release kinetics comprising: (a) carbamazepine or the derivative thereof; (b) an erodible polymeric matrix comprising at least one hydrophilic polymer or a mixture of two or more hydrophilic polymers, having viscosity between about 3 and about 100,000 mpa.s (cp) at concentration of 2% at 20.degree. C. and a molecular weight between about 10,000 and about 246,000; wherein said composition erodes and releases carbamazepine or the derivative thereof in a zero-order release kinetics. 2. The composition of claim 1 wherein said carbamazepine derivative is selected from the group consisting of: 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide/(oxcarbazepine); 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide; 10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-benzoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(3-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(3-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(3-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-acetoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-propionyloxy-10,11-dihydro-5-dibenz/b,f/azepine-5-carboxamide; 10-butyryloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-pivaloyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-[(2-propyl) pentanoyloxy]-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-[(2-ethyl)hexanoyloxy]-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-stearoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-cyclopentanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-cyclohexanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-phenylacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-(3-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide 10-(4-nitrophenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-(3-nitrophenyl)acetoxy-10,11-dihydro-5H dibenz/b,f/azepine-5-carboxamide; 10-nicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-isonicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-aminobutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-amino-3-methylbutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/ -azepine-5-carboxamide; 10-chloroacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-bromoacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-formyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-ethoxycarbonyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-chloropropionyloxy)-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-hydroxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-benzyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-acetyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-propionyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10-butyroyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-propionyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10[(1-napthoyloxy)imino]-5H-dibenz/b,f/azepine-5-carboxamide; 10-benzyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-succinoyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-glutaroyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-isobutoxycarbonyloxyimino-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-methoxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-(S)-(-)-camphanoyloxyimino-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-[(3-methoxybenzoyloxyimino)]-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-nicotinoyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-ethoxycarbonyloxyimino-5H-dibenz/b,f/ azepine-5-carboxamide; 10-butoxycarbonyloxyimino-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; and 10-benzyloxycarbonyloxyimino-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide. 3. The composition according to claim 2 wherein said hydrophilic polymer is selected from the group consisting of methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose. 4. The composition according to claim 3 wherein said polymer is hydroxypropyl methylcellulose. 5. The composition according to claim 4 wherein said matrix is formulated as an erodible tablet. 6. The composition according to claim 5 additionally containing a hydrophobic component. 7. The composition according to claim 6 wherein the hydrophobic component is selected from the group consisting of cellulose derivatives such as ethyl cellulose fats such as glycerol palmitostearate, beeswax, glycowax, castrowax, carnaubawax, glycerol monostearate or stearylalcohol, a hydrophobic polyacrylamide derivative and a hydrophobic methacrylic acid derivative. 8. The composition according to claim 7 wherein hydrophobic cellulose derivative is ethyl cellulose. 9. The composition according to claim 8 additionally containing a pharmaceutically acceptable constituent and additive selected from the group consisting of a protein, arabinogalactan, chitosan, a polysaccharide, a hydrophilic polyacrylamide derivative and a hydrophilic methacrylic acid derivative. 10. The composition according to claim 9 wherein said protein is bovine albumin, human albumin, egg albumin, soy protein, gelatin or casein in the native or denatured state. 11. The composition according to claim 10 wherein said polysaccharide is .beta.-cyclodextran or a starch derivative. 12. The composition according to claim 11 wherein said fat is glycerol palmitostearate, beeswax, glycowax, castrowax, carnaubawax, glycerol monostearate or stearyl alcohol. 13. The composition according to claim 12 further comprising a pharmaceutically acceptable additive selected from the group consisting of a salt, polyethylene glycol and a surfactant. 14. An erodible tablet for oral sustained delivery of carbamazepine or a derivative thereof released from the tablet in a zero-order release kinetics, said tablet comprising carbamazepine or a derivative thereof selected from the group consisting of: 10,11-dihydro-10-oxo-5H-dibenz/b,f/azepine-5-carboxamide/(oxcarbazepine); 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide; 10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-benzoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(3-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(3-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(3-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-acetoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-propionyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-butyryloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-pivaloyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-[(2-propyl)pentanoyloxy]-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-[(2-ethyl)hexanoyloxy]-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-stearoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-clopentanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-cyclohexanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-phenylacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ -azepine-5-carboxamide; 10-(3-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ -azepine-5-carboxamide; 10-(4-nitrophenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-(3-nitrophenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10-nicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-isonicotinoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(4-aminobutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-amino-3-methylbutanoyloxy)-10,11-dihydro-5H-dibenz/b,f/ -azepine-5-carboxamide; 10-chloroacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-bromoacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-formyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-ethoxycarbonyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-(2-chloropropionyloxy)-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-hydroxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-benzyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10-acetyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-propionyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10-butyroyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-pivaloyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-[(1-napthoyloxy)imino]-5H-dibenz/b,f/ azepine-5-carboxamide; 10-benzoyloxyimino-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-succinoyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-glutaroyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-isobutoxycarbonyloxyimino-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-methoxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-(S)-(--)-camphanoyloxyimino 5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-[(3-ethoxybenzoyloxyimino)]-5H-dibenz/b,f/ azepine-5-carboxamide; 10,11-dihydro-10-nicotinoyloxyimino-5H-dibenz/b,f/azepine-5-carboxamide; 10,11-dihydro-10-ethoxycarbonyloxyimino-5H-dibenz/b,f/ azepine-5-carboxamide; 10-butoxycarbonyloxyimino-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide; and 10-benzyloxycarbonyloxyimino-10,11-dihydro-5H-dibenz/b,f/ azepine-5-carboxamide formulated in a polymeric matrix comprising a mixture of at least one hydrophilic polymer and at least one hydrophobic polymer, wherein said hydrophilic polymer having viscosity between about 3 and about 100,000 mPa.s(cp) at concentration of 2% at 20.degree. C. and a molecular weight between about 10,000 and about 246,000; wherein said composition erodes and releases carbamazepine or the derivative thereof in a zero-order release kinetics. 15. The tablet according to claim 14 wherein said hydrophilic polymer is selected from the group consisting of methyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose and wherein said hydrophobic polymer is selected from hydrophobic cellulose derivatives, fats, hydrophobic polyacrylamide and polyamide derivatives, and hydrophobic methacrylic acid derivatives. 16. The formulation tablet according to claim 15 additionally containing proteins, arabinogalactan, chitosan, polysaccharides, hydrophilic polyacrylamide and hydrophilic methacrylic acid derivatives. 17. The tablet according to claim 16 further comprising a pharmaceutically acceptable additive selected from salts, polyethylene glycol and surfactants. 18. The formulation tablet according to claim 17 formulated in dosage unit form. 19. A method for a sustained and controlled zero-order release kinetics of drug delivery comprising: (a) preparation of erodible formulation in form of an erodible tablet, erodible capsule or erodible granules comprising a matrix consisting of carbamazepine or a carbamazepine derivative in admixture with a hydrophilic polymer having a viscosity between about 3 and about 100,000 mpa.s cp concentration of 2% at 20 or in admixture with a mixture of the hydrophilic and a hydrophobic polymer; and (b) administering said erodible formulation orally to a patient wherein upon contact of the erodible formulation with aqueous condition of the digestive system, the formulation erodes at a zero-order release kinetics and releases carbamazepine or a derivative thereof in the zero-order release kinetics.

Details for Patent 6,296,873

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2017-01-23
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2017-01-23
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2017-01-23
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2017-01-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.